---
schema_version: "secwatch.filing_event.v1"
accession: "0002046386-26-000007"
form_type: "8-K"
ticker: "MDLN"
cik: "0002046386"
company_name: "Medline Inc."
filed_at: "2026-02-25T23:59:59+00:00"
generated_at: "2026-05-16T00:30:46.293783+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Medline Q4 net income down 37.7% to $180M; FY25 EBITDA up 3.2%; guides FY26 organic sales growth 8-9%

## Summary
- Q4 net sales $7.8B (+14.8% YoY); net income $180M (-37.7%); Adj. EBITDA $805M (flat).
- FY25 net sales $28.4B (+11.5%); net income $1.2B (-3.6%); Adj. EBITDA $3.5B (+3.2%).
- FY25 organic sales growth 10.5%; net cash from ops $1.7B; Free Cash Flow $1.3B.
- FY26 guidance: organic sales growth 8-9%; Adj. EBITDA $3.5-3.6B.
- Margins pressured by tariffs and higher costs; $2.4B in new customer signings in 2025.

## SEC filing metadata
- accession: 0002046386-26-000007
- form_type: 8-K
- ticker: MDLN
- cik: 0002046386
- company_name: Medline Inc.
- filed_at: 2026-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2046386/000204638626000007/0002046386-26-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2046386/000204638626000007/mdln-20260225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0002046386-26-000007
- JSON: https://secwatch.observer/filing/0002046386-26-000007.json
- Plain text: https://secwatch.observer/filing/0002046386-26-000007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.